JP2016503803A5 - - Google Patents

Download PDF

Info

Publication number
JP2016503803A5
JP2016503803A5 JP2015549792A JP2015549792A JP2016503803A5 JP 2016503803 A5 JP2016503803 A5 JP 2016503803A5 JP 2015549792 A JP2015549792 A JP 2015549792A JP 2015549792 A JP2015549792 A JP 2015549792A JP 2016503803 A5 JP2016503803 A5 JP 2016503803A5
Authority
JP
Japan
Prior art keywords
weight percent
amount
glatiramer acetate
oral tablet
hydroxypropylcellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015549792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503803A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/077034 external-priority patent/WO2014100639A1/en
Publication of JP2016503803A publication Critical patent/JP2016503803A/ja
Publication of JP2016503803A5 publication Critical patent/JP2016503803A5/ja
Withdrawn legal-status Critical Current

Links

JP2015549792A 2012-12-21 2013-12-20 酢酸グラチラマーの経粘膜送達 Withdrawn JP2016503803A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745226P 2012-12-21 2012-12-21
US61/745,226 2012-12-21
PCT/US2013/077034 WO2014100639A1 (en) 2012-12-21 2013-12-20 Transmucosal delivery of glatiramer acetate

Publications (2)

Publication Number Publication Date
JP2016503803A JP2016503803A (ja) 2016-02-08
JP2016503803A5 true JP2016503803A5 (enExample) 2017-02-02

Family

ID=50979257

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015549792A Withdrawn JP2016503803A (ja) 2012-12-21 2013-12-20 酢酸グラチラマーの経粘膜送達

Country Status (15)

Country Link
US (1) US20160193276A1 (enExample)
EP (1) EP2934492A4 (enExample)
JP (1) JP2016503803A (enExample)
KR (1) KR20150111918A (enExample)
CN (1) CN104869983A (enExample)
AU (1) AU2013361053A1 (enExample)
BR (1) BR112015014095A2 (enExample)
CA (1) CA2895359A1 (enExample)
EA (1) EA201591188A1 (enExample)
HK (2) HK1214523A1 (enExample)
IL (1) IL239280A0 (enExample)
MX (1) MX2015007678A (enExample)
SG (1) SG11201504422XA (enExample)
WO (1) WO2014100639A1 (enExample)
ZA (1) ZA201505049B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2627669T3 (pl) 2010-10-11 2017-02-28 Teva Pharmaceutical Industries Ltd. Biomarkery cytokinowe jako biomarkery prognostyczne odpowiedzi klinicznej na octan glatirameru
EP2765857A4 (en) 2011-10-10 2015-12-09 Teva Pharma SIMPLE NUCLEOTIDE POLYMORPHISMS USEFUL FOR PREDICTING CLINICAL RESPONSE TO GLATIRAMERATE ACETATE
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
WO2015140790A1 (en) 2014-03-17 2015-09-24 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
CN106924175B (zh) * 2015-12-29 2020-07-03 深圳翰宇药业股份有限公司 一种治疗多发性硬化症的药物组合物
WO2017138645A1 (ja) * 2016-02-12 2017-08-17 テイカ製薬株式会社 乾式造粒物及び該乾式造粒物を含有する固形製剤並びにそれらの製造方法
WO2019002228A1 (en) 2017-06-26 2019-01-03 Institut Pasteur TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200206457B (en) * 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
EP1261361B1 (en) * 2000-02-18 2006-06-14 Yeda Research And Development Company, Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1 (glatiramer acetate)
IL159715A0 (en) * 2001-07-10 2004-06-20 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
PT1848415E (pt) * 2005-02-17 2013-06-27 Teva Pharma Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla
CN101312714A (zh) * 2005-11-22 2008-11-26 特瓦制药工业有限公司 替米沙坦的药用组合物
WO2007074472A2 (en) * 2005-12-27 2007-07-05 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide
EA018573B1 (ru) * 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
ES2329327B1 (es) * 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.

Similar Documents

Publication Publication Date Title
JP2016503803A5 (enExample)
CA2251886C (en) An oral pharmaceutical formulation containing ibandronate
Sharma et al. A comprehensive review on fast dissolving tablet technology
JP2018517715A5 (enExample)
JP2006505566A5 (enExample)
JP2011509295A5 (enExample)
JP2016522191A (ja) ロスバスタチンまたはその薬学的に許容可能な塩を含有する膜コーティング層を含む複合製剤
JP2014221827A5 (enExample)
JP2018521985A5 (enExample)
SI3106148T1 (en) ORODISPERSIBILITY DOSING UNIT, CONTAINING ESTETROL COMPONENT
JP5810819B2 (ja) 積層錠
TWI480067B (zh) 經包衣之固體製劑
JP2010143836A (ja) 口腔内崩壊錠用組成物
JP2018118966A5 (enExample)
JP2018039810A5 (enExample)
RU2018137590A (ru) Фармацевтические композиции для производного n-пропаргиламина
CA2648538A1 (en) Oral rapid release pharmaceutical formulation for pyridylmethylsulfinyl-benzimidazoles
CN102958522B (zh) 微粒包衣制剂
JPH05246845A (ja) イブプロフェン含有解熱鎮痛剤
KR101531030B1 (ko) 미르타자핀 함유 구강붕해정
JP2010241760A (ja) 不快な味の軽減された口腔内速崩壊錠及びその製造方法
JP2010168287A (ja) 内服用錠剤
WO2015008825A1 (ja) 口腔内崩壊錠
JP2017511350A5 (enExample)
JP2010509293A5 (enExample)